Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Jasper and its executives made false statements regarding the company's manufacturing controls and the implications for its product, briquilimab [6][7]. Group 2: Company Performance and Stock Impact - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [7]. - The company announced a halt in the development of briquilimab for asthma and SCID, contradicting previous claims of a strong financial position [7].